Comparative trial of tolerability, reactogenicity, safety and immunogenicity of the Flu-M vaccine as compared to the Vaxigrip® vaccine in terms of prevention of influenza in children aged 6 months to 9 years (at the time of the first vaccination).
The trial includes 2 stages (stage I, II). At stage I children aged 3-9 years will be included. Based on findings from tolerability and safety assessment in respect of the Flu-M vaccine vs. the Vaxigrip® vaccine for the first 7 days after vaccination of volunteers during Stage I, an intermediate report will be prepared. The report will be submitted to the supervisory executive authorities alongside the notice of commencement of Stage II of the trial - the continuation of trial on children aged 3-9 years and the commencement of trial on children aged between 6 months and 35 months. During Stage II, the trial for Stage I volunteers will continue in full and also children aged between 6 and 35 months will be included in the trial.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
1,066
Solution for intramuscular injection Сhildren were vaccinated with the Flu-M vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine once/twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination; if the child is vaccinated for the first time) intramuscularly in a dose of 0.5 mL
LLC "Energiya zdorov'ya"
Saint Petersburg, Russia
St. Petersburg State Budgetary Institution of Health Care "Children's City Polyclinic No. 45" of the Nevsky District
Saint Petersburg, Russia
Change from Baseline seroconversion level
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) The upper limit of bilateral 95 % CI for the difference between seroconversion levels (seroconversion level reference vaccine - the seroconversion level trial vaccine) should not exceed 10%. Seroconversion ≥ 40%
Time frame: Days 0 (screening), 28, 56, 180 after vaccination/revaccination
Change from Baseline Geometric mean titer (GMT) of antibodies
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) The upper limit of bilateral 95% CI for the GMT ratio (GMTreference vaccine/GMTtrial vaccine) should not exceed 1.5
Time frame: Days 0 (screening), 28 after vaccination/revaccination
Change from Baseline Seroconversion factor
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) Seroconversion factor ≥ 2.5
Time frame: Days 0 (screening), 28, 56, 180 after vaccination/revaccination
Change from Baseline Seroprotection rate
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) Seroprotection ≥ 70%
Time frame: Days 0 (screening), 28, 56, 180 after vaccination/revaccination
Change from Baseline Seroconversion rate for each virus strain
Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay)
Time frame: Days 0 (screening), 28, 56, 180 after vaccination/revaccination
Incidence of immediate adverse events (allergic reactions)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Solution for intramuscular injection Children were vaccinated with the Flu-M vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
Suspension for intramuscular and subcutaneous injection Children were vaccinated with the Vaxigrip® vaccine twice (all children were vaccinated twice with an interval of 28 days between the first vaccination and revaccination) intramuscularly in a dose of 0.25 mL
Anaphylaxis, Quincke's edema, Urticaria.
Time frame: 2 hours after vaccination/revaccination
Incidence of local adverse events
Pain at the injection site at palpation, Hyperemia at the injection site, infiltrate at the injection site, Edema at the injection site, Pruritus at the injection site, Enlarged regional lymph nodes.
Time frame: Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180
Incidence of systemic adverse events
Headache, Cough, Sore throat, Nausea, Increased sweating, Arthralgia, Myalgia, Fever, Chills, Asthenia
Time frame: Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180
Incidence of severe adverse events during the trial
Time frame: Day 1 (2 and 5-8 hours after vaccination/revaccination), days 2-180
Number of participants with abnormal changes in physical examination data
Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion; examination of skin, mucosa, eyes, oral cavity and pharynx, lungs/chest, heart/cardiovascular system, abdominal organs, nervous system, lymph nodes, musculoskeletal system.
Time frame: Days 0 (screening), 3, 7, 28, 56
Number of participants with abnormal changes of neurological status
Time frame: Days 0 (screening), 3, 7, 28, 56
Number of participants with abnormal changes in vital signs - Blood pressure (BP)
BP measurements include the systolic and diastolic blood pressure.
Time frame: Days 0 (screening), 3, 7, 28, 56
Number of participants with abnormal changes in vital signs - Heart rate (HR)
HR is measured using a phonendoscope at the apex of the heart during 1 minute.
Time frame: Days 0 (screening), 3, 7, 28, 56
Number of participants with abnormal changes in vital signs - Respiratory rate (RR)
RR is counted with a hand placed on the child's chest or abdomen or by holding a stethoscope at the child's nose. The measurement is carried out during one minute.
Time frame: Days 0 (screening), 3, 7, 28, 56
Number of participants with abnormal changes in vital signs - Body temperature
Measurement with a digital thermometer.
Time frame: Day 0 (screening); 10 min before, 20 min and 2 hours after vaccination; days 3, 7, 28, 56
Number of participants with clinically significant abnormalities - Complete blood count (CBC)
Hemoglobin, hematocrit, erythrocytes, leukocytes, leukocytic formula, platelets, erythrocyte sedimentation rate (ESR).
Time frame: Days 0 (screening), 3
Number of participants with clinically significant abnormalities - Biochemical blood test (BBT)
ALT, AST, LDH, alkaline phosphatase, total bilirubin, urea, glucose.
Time frame: Days 0 (screening), 3
Number of participants with clinically significant abnormalities - Urinalysis
pH, specific density, protein, glucose, erythrocytes, leukocytes.
Time frame: Days 0 (screening), 3
Number of participants with abnormal changes of total IgE
Time frame: Days 0 (screening), 3, 56